Although several studies demonstrated that the expression of PDL1 could predict the clinical response to anti-PDL1 treatment in multi-tumors [5–7], some clinical trials indicated that PDL1 combined positive score (CPS) had a poor power to predict the overall survival and objective response rate (ORR) between nivolumab plus chemotherapy treatment groups and chemotherapy alone treatment groups in advanced gastric/gastro-oesophageal junction/oesophageal adenocarcinoma [4, 8]. The gene discussed is CD274; the disease is esophageal adenocarcinoma.